Early Diagnosis of Gastric Cancer Cachexia
Clinical Value of Tumor Cell-derived Exosomal miRNA in Early Diagnosis of Gastric Cancer Cachexia
1 other identifier
observational
150
1 country
1
Brief Summary
Gastric cancer is one of the most common malignancies, the morbidity and mortality of which are among the highest. In cancer patients, the incidence of cachexia is very high, and even 80% of patients will eventually develop into cachexia. However, once gastric cancer patients develop cachexia, patients are unlikely to obtain clinically significant benefits from conventional treatment. Therefore, it is important to find biomarkers for early detection of cachexia. The investigators carried out a plasma-derived exosomal microRNA(miRNA) study for early diagnosis of cachexia in gastric cancer, and the development of early diagnosis kits for gastric cancer cachexia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2021
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2021
CompletedFirst Submitted
Initial submission to the registry
January 16, 2022
CompletedFirst Posted
Study publicly available on registry
February 26, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2024
CompletedFebruary 26, 2024
January 1, 2024
3.3 years
January 16, 2022
February 18, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
BMI
Calculate BMI based on changes in body weight in the past six months
six months
Study Arms (2)
Gastric cancer patients with non-cachexia
Gastric cancer patients with cachexia
Interventions
Cachexia mainly manifests as weight loss. 1)weight loss \>5% over past 6 months. 2)BMI\<20 and any degree of weight loss \>2%. 3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss \>2%.
Eligibility Criteria
The research object is patients with confirmed gastric cancer.According to diagnostic criteria, patients are divided into cachexia group and non-cachexia group.
You may qualify if:
- Patients with gastric cancer diagnosed by histopathology or cytopathology
- Complete clinical and pathological data
- No previous or current mental illness or disturbance of consciousness
You may not qualify if:
- With multiple tumors or other malignant diseases
- Combined with other chronic wasting and metabolic diseases
- Past patients with non-tumor cachexia
- People with mental illness or unable to cooperate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Xijing Hospitallead
Study Sites (1)
Fourth Military Medical University
Xi'an, Shaanxi, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 16, 2022
First Posted
February 26, 2024
Study Start
June 1, 2021
Primary Completion
September 1, 2024
Study Completion
September 1, 2024
Last Updated
February 26, 2024
Record last verified: 2024-01